Zambon Join Forces With Catalent To Timely Deliver Xadago®

Summary: Safinamide is the first new molecule in 20 years, to be used in the treatment of Parkinson’s. Zambon s.p.A. entrusted Catalent as its partner for timely development and launch of Safinamide under the brand name Xadago® to a worldwide target market.

Click here to download Case Study.